18:28 , Nov 30, 2018 |  BC Week In Review  |  Financial News

Feldan brings series A total to $13.8M

Feldan Therapeutics Inc. (Quebec, Quebec) raised an additional $1.3 million from Asahi Kasei Corporate Venture Capital on Nov. 27 for its series A round, bringing the round's total to $13.8 million. Felden will use the...
20:46 , Oct 10, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Ataxia Cell culture studies suggest inhibiting NF-κB could help treat spinocerebellar ataxia type 17 (SCA17), which is caused by CAG/CAA repeat expansions in the TBP gene. In co-cultures of primary neurons and astrocytes from...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Financial News

Thorasys completes venture financing

Thorasys Thoracic Medical Systems Inc. , Montreal, Quebec   Business: Pulmonary   Date completed: 2016-08-25   Type: Venture financing   Raised: C$1.3 million ($1 million)   Investor: Anges Quebec  ...
07:00 , Aug 8, 2016 |  BC Week In Review  |  Financial News

Vical completes private placement

Vical Inc. (NASDAQ:VICL), San Diego, Calif.   Business: Gene/Cell therapy, Infectious, Cardiovascular   Date completed: 2016-08-01   Type: Private placement   Raised: $7.8 million   Shares: 1.8 million   Price: $4.24   Shares after offering:...
07:00 , Mar 21, 2016 |  BC Week In Review  |  Financial News

Laurent Pharmaceuticals completes venture financing

Laurent Pharmaceuticals Inc. , Montreal, Quebec   Business: Pulmonary   Date completed: 2016-03-17   Type: Venture financing   Raised: Not disclosed   Investors: Cystic Fibrosis Canada; Aligo Innovation; Anges Quebec; existing investors; private investors  ...
07:00 , Oct 27, 2014 |  BC Week In Review  |  Clinical News

Collategene beperminogene perplasmid: Phase III started

AnGes began a double-blind, placebo-controlled, international Phase III trial to evaluate Collategene injected into the affected limb for 36 months in about 500 patients with CLI. AnGes has an SPA from FDA for the trial....
07:00 , Jun 5, 2014 |  BC Innovations  |  Strategy

Sanford-Burnham goes fourth

Sanford-Burnham Medical Research Institute 's outreach to industry has resulted historically in deals focused either on a narrow range of projects or the work of individual investigators, but the institute also has been seeking broader...
08:00 , Mar 6, 2014 |  BC Innovations  |  Targets & Mechanisms

Heart cells: no longer undivided

The inability of adult heart cells to divide rapidly enough to repair cardiac damage has been a major impediment to regenerating heart tissue and preventing fibrosis after myocardial infarction. Now, a U.S. team has used...
08:00 , Dec 9, 2013 |  BC Week In Review  |  Clinical News

Allovectin velimogene aliplasmid: Additional Phase III data

Additional data from the single-blind, international Phase III AIMM trial in 390 chemotherapy-naïve patients with recurrent stage III or IV metastatic melanoma showed that 2 mg intralesional Allovectin led to an ORR at >=24 weeks,...
08:00 , Nov 25, 2013 |  BC Week In Review  |  Financial News

AnGes financial update

AnGes plans to implement a 100-for-1 stock split. Following the split, the company will have about 31.3 million shares outstanding. AnGes MG Inc. (Tokyo:4563), Osaka, Japan   Business: Cardiovascular, Autoimmune, Gene/Cell therapy   Date announced:...